ProgynyPGNY
PGNY
About: Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Employees: 680
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
179% more call options, than puts
Call options by funds: $8.57M | Put options by funds: $3.07M
2.06% more ownership
Funds ownership: 95.64% [Q3] → 97.7% (+2.06%) [Q4]
2% more capital invested
Capital invested by funds: $1.4B [Q3] → $1.44B (+$30.8M) [Q4]
7% less funds holding
Funds holding: 283 [Q3] → 262 (-21) [Q4]
20% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 96
25% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 72
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
6%
downside
Avg. target
$25
10%
upside
High target
$28
26%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Canaccord Genuity Richard Close 43% 1-year accuracy 10 / 23 met price target | 6%downside $21 | Hold Maintained | 12 May 2025 |
BTIG David Larsen 50% 1-year accuracy 6 / 12 met price target | 26%upside $28 | Buy Upgraded | 31 Mar 2025 |
Financial journalist opinion
Based on 11 articles about PGNY published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. “As Progyny continues to be at the forefront of women's health, we are proud to welcome two deeply respected clinical leaders whose unique training and lived experience will bring critical insights to our work,” said Dr. Janet Choi, Chief Medical Officer at Progyny.
Neutral
GlobeNewsWire
4 days ago
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time.
Neutral
Seeking Alpha
1 week ago
Progyny, Inc. (PGNY) Q1 2025 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q1 2025 Results Conference Call May 8, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Pete Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities David Larsen - BTIG Sarah James - Cantor Fitzgerald Operator Good day, ladies and gentlemen, and welcome to the Progyny Inc. First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode and the floor will be opened for questions and comments after the presentation.
Positive
Zacks Investment Research
1 week ago
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Progyny, Inc. Announces First Quarter 2025 Results
Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 (“the first quarter of 2025”) as compared to the three-month period ended March 31, 2024 (“the first quarter of 2024” or “the prior year period”). “We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building,” said Pete Anevski, Chief Executive Officer of Progyny.
Positive
Zacks Investment Research
1 week ago
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors?
Positive
Zacks Investment Research
2 weeks ago
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 weeks ago
Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025.
Positive
Zacks Investment Research
3 weeks ago
Why Progyny (PGNY) is Poised to Beat Earnings Estimates Again
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
GlobeNewsWire
4 weeks ago
Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer
The leadership additions support the company's continued ability to scale as it delivers the right care model for women's health and family building The leadership additions support the company's continued ability to scale as it delivers the right care model for women's health and family building
Charts implemented using Lightweight Charts™